What is claimed is:

1. A method of treating a proliferative disease comprising administering a compound of the Formula (I)



(I)

wherein:
R_2 is substituted or unsubstituted aryl, substituted or unsubstituted bicyclic aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted bicyclic heteroaryl;

R'_6 is H or lower alkyl;

R_8 is H, halo, lower alkyl, lower alkenyl, small cycloalkyl, acetyl, $-NR_{12}R_{13}$ where R_{12} and R_{13} are independently H or lower alkyl;

R_6 is substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted bicyclic aryl, substituted or unsubstituted bicyclic heteroaryl, or a substituted or unsubstituted aliphatic residue; or R_6 and R'_6 with the N atom form a substituted or unsubstituted heterocyclic radical;

or pharmaceutically acceptable salts thereof,

to a warm-blooded animal, especially a human, in need of such treatment: or pharmaceutically acceptable salts thereof.

2. A method according to Claim 1, wherein the proliferative disease is a benign or malignant tumor, a carcinoma of the brain, kidney, liver, adrenal gland, bladder, breast, stomach, gastric tumors, ovaries, colon, rectum, prostate, pancreas, lung, vagina, thyroid, sarcoma, glioblastomas, multiple myeloma or gastrointestinal cancer, colon carcinoma or colorectal adenoma, or a tumor of the neck and head, an epidermal hyperproliferation, prostate hyperplasia, a neoplasia, or a leukemia.

3. A method according to Claim 1 wherein the proliferative disease is selected from cancers and tumors with low levels of topoisomerase II.

4. A compound of Formula (I):



(I)

wherein:

R_2 is substituted or unsubstituted aryl, substituted or unsubstituted bicyclic aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted bicyclic heteroaryl;

R'_6 is H or lower alkyl;

R_8 is lower alkyl or small cycloalkyl;

R_6 is substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted bicyclic aryl, substituted or unsubstituted bicyclic heteroaryl, or a substituted or unsubstituted aliphatic residue; or R_6 and R'_6 with the N atom form a substituted or unsubstituted heterocyclic radical;
or pharmaceutically acceptable salts thereof.

5. A compound of Formula (I) according to claim 4 wherein:

R_2 is phenyl; phenyl substituted with thiazolyl; benzothiazolyl; benzothioazoyl substituted with lower alkyl such as methyl or t-butyl or substituted with lower alkyl sulfanyl such as methyl sulfanyl; quinolinyl; quinolinyl substituted with methyl; naphthyl; indolyl; benzo[1,2,5]thiadiazolyl; chromenyl; chromen-2-one or amino chromen-2-one; and

R_6 is cycloheptyl; cyclooctyl; cycloheptyl; cyclohexyl or cyclohexyl substituted with hydroxy; adamantanyl; bicyclo[2.2.1] heptyl; phenyl or phenyl substituted with lower alkoxy, e.g. methoxy; quinolinyl; lower alkyl such as t-butyl; 2,2,2-trifluoro-1-methyl-ethyl-; methyl or methyl substituted with diphenyl; ethyl or ethyl substituted with methyl and fluorophenyl, e.g. 2-(fluoro-phenyl)-1,1-dimethyl-ethyl; propyl or propyl substituted with methyl or hydroxy e.g. 1,1-dimethyl propyl or 1-hydroxy-2-methyl-prop-2-yl; lower aliphatic ester e.g. 3-yl-butyric acid ethyl ester or amide 3-yl-butyramide;

R_6 R'_6N is piperazinyl substituted with pyridine or pyrazine; or pyrrolidin-1-yl e.g. 2-methyl-pyrrolidin-1-yl;

or pharmaceutically acceptable salts thereof.

6. A compound according to claim 4 wherein R_2 is aryl or heteroaryl substituted with R'_2 where R'_2 is H or a solubilizing group of the Formula:

–X-Y-A

where X is O, S, $-(CH_2)_n-$, NH or N(lower alkyl);

Y is $-(CH_2)_n-$;

n is 1-4, preferably 2-3; and

A is $NR_{10}R_{11}$ where R_{10} and R_{11} are independently H or C_1-C_3 lower alky, such as methyl, ethyl or propyl, or R_{10} and R_{11} with the nitrogen atom form a 3- to 8-membered heterocyclic ring containing 1-4 nitrogen, oxygen or sulfur atoms (e.g. morpholinyl, piperazinyl or lower alkyl-piperazinyl) or A is



where X is as defined above.

7. A compound according to claim 6 wherein R_2 is selected from



and



8. A compound according to claims 1 wherein R_6 is bicyclic alkyl, tricyclic alkyl, or heteroaryl, all of which may be substituted or unsubstituted.

9. A compound according to Formula (II):



(II)

R'_6 is H or lower alkyl; R_8 is H, halo or lower alkyl; small cycloalkyl, and

R_6 is substituted or unsubstituted aryl, substituted or unsubstituted bicyclic aryl or a substituted or unsubstituted aliphatic residue, or a substituted or unsubstituted aliphatic ester or amide

or R_6 and R'_6 with the N form a heterocyclic radical;

Y is a protecting group selected from chlorine, bromine or iodine

or pharmaceutically acceptable salts thereof, with the proviso that if R_8 is H, then R'_6 cannot be bicyclo[2.2.1]hept-2-ylamine, methoxyphenyl or phenyl.

10. A compound of Formula (III):



(III)

wherein:
R_2 is substituted or unsubstituted aryl, substituted or unsubstituted bicyclic aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted bicyclic heteroaryl;

R'_6 is H or lower alkyl;

R_8 is H, halo, lower alkyl, lower alkenyl, small cycloalkyl, acetyl, $-NR_{12}R_{13}$ where R_{12} and R_{13} are independently H or lower alkyl;

R_9 is a protecting group;

R_6 is substituted or unsubstituted aryl, substituted or unsubstituted bicyclic aryl or a substituted or unsubstituted aliphatic residue,

or R_6 and R'_6 with the N form a heterocyclic radical;
or pharmaceutically acceptable salts thereof.

11. A compound of Formula (IV):



(IV)

wherein:

R'_6 and R_8 are each independently H, halo, or lower alkyl;

R_9 is a protecting group;

Y is a protecting group selected from chlorine, bromine or iodine;

R_6 is substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted bicyclic aryl, substituted or unsubstituted bicyclic heteroaryl, or a substituted or unsubstituted aliphatic residue; or R_6 and R'_6 with the N atom form a substituted or unsubstituted heterocyclic radical;

or pharmaceutically acceptable salts thereof.

12. A compound of Formula (V):



(V)

R_8 is H, halo or lower alkyl and Y is a protecting group selected from chlorine, bromine or iodine.

13. A pharmaceutical composition comprising a compound according to Claim 4.

14. A pharmaceutical composition comprising a compound according to Claim 4 and an acceptable pharmaceutical carrier.

15. A compound according to Claim 1 selected from the group consisting of:
N*2*-Benzothiazol-6-yl-N*6*-cycloheptyl-9H-purine-2,6-diamine;
N*6*-Cycloheptyl-N*2*-(4-thiazol-2-yl-phenyl)-9H-purine-2,6-diamine;
N*6*-Cycloheptyl-N*2*-quinolin-6-yl-9H-purine-2,6-diamine;
2-[2-(Benzothiazol-6-ylamino)-9H-purin-6-ylamino]-2-methyl-propan-1-ol;

N*6*-Adamantan-2-yl-N*2*-benzothiazol-6-yl-9H-purine-2,6-diamine;

N*2*-Benzothiazol-6-yl-N*6*-bicyclo[2.2.1]hept-2-yl-9H-purine-2,6-diamine;

N*2*-Benzothiazol-6-yl-N*6*-cyclooctyl-9H-purine-2,6-diamine;

N*2*-Benzothiazol-6-yl-N*6*-(3-methoxy-phenyl)-9H-purine-2,6-diamine;

4-[2-(Benzothiazol-6-ylamino)-9H-purin-6-ylamino]-cyclohexanol;

N*2*,N*6*-Di-quinolin-6-yl-9H-purine-2,6-diamine;

N*6*-Benzhydryl-N*2*-benzothiazol-6-yl-9H-purine-2,6-diamine;

N*6*-Phenyl-N*2*-quinolin-6-yl-9H-purine-2,6-diamine;

N*6*-Benzhydryl-N*2*-quinolin-6-yl-9H-purine-2,6-diamine;

N*6*-tert-Butyl-N*2*-naphthalen-2-yl-9H-purine-2,6-diamine;

N*6*-tert-Butyl-N*2*-(2-methyl-quinolin-6-yl)-9H-purine-2,6-diamine;

N*6*-tert-Butyl-N*2*-(2-methyl-benzothiazol-5-yl)-9H-purine-2,6-diamine;

N*6*-tert-Butyl-N*2*-(2-tert-butyl-benzothiazol-6-yl)-9H-purine-2,6-diamine;

N*6*-tert-Butyl-N*2*-(2-methyl-benzothiazol-6-yl)-9H-purine-2,6-diamine;

N*2*-(4-Benzothiazol-2-yl-phenyl)-N*6*-tert-butyl-9H-purine-2,6-diamine;

N*6*-tert-Butyl-N*2*-(6-methoxy-naphthalen-2-yl)-9H-purine-2,6-diamine;

N*6*-tert-Butyl-N*2*-[6-(2-morpholin-4-yl-ethoxy)-naphthalen-2-yl]-9H-purine-2,6-diamine;

N*6*-tert-Butyl-N*2*-(2-methyl-1H-indol-5-yl)-9H-purine-2,6-diamine;

N*6*-tert-Butyl-N*2*-(1H-indol-5-yl)-9H-purine-2,6-diamine;

N*2*-Benzothiazol-6-yl-N*6*-tert-butyl-8-methyl-9H-purine-2,6-diamine;

N*2*-Benzothiazol-6-yl-N*6*-cycloheptyl-8-methyl-9H-purine-2,6-diamine;

N*2*-Benzothiazol-6-yl-N*6*-tert-butyl-8-ethyl-9H-purine-2,6-diamine;

N*2*-Benzothiazol-6-yl-8-ethyl-N*6*-(2,2,2-trifluoro-1-methyl-ethyl)-9H-purine-2,6-diamine;

Benzothiazol-6-yl-[8-ethyl-6-(2-methyl-pyrrolidin-1-yl)-9H-purin-2-yl]-amine;

3-[2-(Benzothiazol-6-ylamino)-8-ethyl-9H-purin-6-ylamino]-butyramide;

3-[2-(Benzothiazol-6-ylamino)-8-ethyl-9H-purin-6-ylamino]-butyric acid ethyl ester;

N*2*-Benzothiazol-6-yl-N*6*-tert-butyl-8-propyl-9H-purine-2,6-diamine;

N*2*-Benzothiazol-6-yl-N*6*-tert-butyl-8-isopropyl-9H-purine-2,6-diamine;

N*2*-Benzothiazol-6-yl-N*6*-tert-butyl-8-cyclopentyl-9H-purine-2,6-diamine;

6-(6-tert-Butylamino-8-ethyl-9H-purin-2-ylamino)-chromen-2-one;

N*6*-tert-Butyl-8-ethyl-N*2*-(2-methylsulfanyl-benzothiazol-6-yl)-9H-purine-2,6-diamine;

N*6*-tert-Butyl-8-ethyl-N*2*-[2-(2-morpholin-4-yl-ethoxy)-benzothiazol-6-yl]-9H-purine-2,6-diamine;

N*6*-tert-Butyl-8-isopropyl-N*2*-{1-methylene-3-[5-methyl-2-(2-morpholin-4-yl-ethoxy)-thiazol-4-yl]-allyl}-9H-purine-2,6-diamine;

N*6*-tert-Butyl-8-cyclopropyl-N*2*-{1-methylene-3-[5-methyl-2-(2-morpholin-4-yl-ethoxy)-thiazol-4-yl]-allyl}-9H-purine-2,6-diamine;

N*6*-tert-Butyl-8-cyclopentyl-N*2*-{1-methylene-3-[5-methyl-2-(2-morpholin-4-yl-ethoxy)-thiazol-4-yl]-allyl}-9H-purine-2,6-diamine;

N*2*-Benzothiazol-6-yl-N*6*-tert-butyl-8-cyclopropyl-9H-purine-2,6-diamine;

N*2*-Benzothiazol-6-yl-N*6*-tert-butyl-9H-purine-2,6,8-triamine;

N*6*-tert-Butyl-N*2*-naphthalen-2-yl-9H-purine-2,6,8-triamine;

N*6*-tert-Butyl-N*8*-methyl-N*2*-naphthalen-2-yl-9H-purine-2,6,8-triamine;

1-[2-(Benzothiazol-6-ylamino)-6-tert-butylamino-9H-purin-8-yl]-ethanone;

N*6*-tert-Butyl-N*2*-quinolin-6-yl-9H-purine-2,6-diamine;

N*2*-Benzo[1,2,5]thiadiazol-5-yl-N*6*-tert-butyl-9H-purine-2,6-diamine;

N*6*-tert-Butyl-N*2*-(2-methyl-benzothiazol-6-yl)-9H-purine-2,6-diamine;

N*2*-Benzo[1,2,5]thiadiazol-5-yl-N*6*-cycloheptyl-9H-purine-2,6-diamine;

N*6*-Cycloheptyl-N*2*-(2-methyl-benzothiazol-6-yl)-9H-purine-2,6-diamine;

N*2*-Benzothiazol-6-yl-N*6*-(1,1-dimethyl-propyl)-9H-purine-2,6-diamine;

N*6*-(1,1-Dimethyl-propyl)-N*2*-quinolin-6-yl-9H-purine-2,6-diamine;

N*2*-Benzo[1,2,5]thiadiazol-5-yl-N*6*-(1,1-dimethyl-propyl)-9H-purine-2,6-diamine;

N*6*-(1,1-Dimethyl-propyl)-N*2*-(2-methyl-benzothiazol-6-yl)-9H-purine-2,6-diamine;

N*2*-Benzothiazol-6-yl-N*6*-[2-(4-fluoro-phenyl)-1,1-dimethyl-ethyl]-9H-purine-2,6-diamine;

N*6*-[2-(4-Fluoro-phenyl)-1,1-dimethyl-ethyl]-N*2*-quinolin-6-yl-9H-purine-2,6-diamine;

N*2*-Benzo[1,2,5]thiadiazol-5-yl-N*6*-[2-(4-fluoro-phenyl)-1,1-dimethyl-ethyl]-9H-purine-2,6-diamine;

N*6*-[2-(4-Fluoro-phenyl)-1,1-dimethyl-ethyl]-N*2*-(2-methyl-benzothiazol-6-yl)-9H-purine-2,6-diamine;

Benzothiazol-6-yl-[6-(4-pyridin-3-yl-piperazin-1-yl)-9H-purin-2-yl]-amine;

Benzothiazol-6-yl-[6-(4-pyridin-2-yl-piperazin-1-yl)-9H-purin-2-yl]-amine;

[6-(4-Pyridin-2-yl-piperazin-1-yl)-9H-purin-2-yl]-quinolin-6-yl-amine;

Benzo[1,2,5]thiadiazol-5-yl-[6-(4-pyridin-2-yl-piperazin-1-yl)-9H-purin-2-yl]-amine;

(2-Methyl-benzothiazol-6-yl)-[6-(4-pyridin-2-yl-piperazin-1-yl)-9H-purin-2-yl]-amine;

Quinolin-6-yl-[6-(2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4-yl)-9H-purin-2-yl]-amine;

N*2*-Benzothiazol-6-yl-N*6*-tert-butyl-9H-purine-2,6-diamine;

N*2*-Benzothiazol-6-yl-N*6*-cycloheptyl-9H-purine-2,6-diamine;

N*6*-Cycloheptyl-N*2*-quinolin-6-yl-9H-purine-2,6-diamine;

2-[2-(Benzothiazol-6-ylamino)-9H-purin-6-ylamino]-2-methyl-propan-1-ol;

8-Bromo-N*6*-tert-butyl-N*2*-naphthalen-2-yl-9H-purine-2,6-diamine;

N*6*-tert-Butyl-N*2*-naphthalen-2-yl-8-vinyl-9H-purine-2,6-diamine;

8-Allyl-N*6*-tert-butyl-N*2*-naphthalen-2-yl-9H-purine-2,6-diamine;
N*6*-tert-Butyl-8-methyl-N*2*-naphthalen-2-yl-9H-purine-2,6-diamine;
N*6*-tert-Butyl-8-ethyl-N*2*-naphthalen-2-yl-9H-purine-2,6-diamine;
N*6*-tert-Butyl-8-isobutyl-N*2*-naphthalen-2-yl-9H-purine-2,6-diamine;
and pharmaceutically acceptable salts thereof.

16. A compound selected from the group consisting of:
(2-Chloro-9H-purin-6-yl)-cycloheptyl-amine;
2-(2-Chloro-9H-purin-6-ylamino)-2-methyl-propan-1-ol;
Adamantan-2-yl-(2-chloro-9H-purin-6-yl)-amine;
(2-Chloro-9H-purin-6-yl)-cyclooctyl-amine;
4-(2-Chloro-9H-purin-6-ylamino)-cyclohexanol;
(2-Chloro-9H-purin-6-yl)-quinolin-6-yl-amine;
Benzhydryl-(2-chloro-9H-purin-6-yl)-amine;
N*6*-Benzhydryl-N*2*-quinolin-6-yl-9-(tetrahydro-pyran-2-yl)-9H-purine-2,6-diamine;
N*2*-Benzothiazol-6-yl-N*6*-tert-butyl-9-(tetrahydro-pyran-2-yl)-9H-purine-2,6-diamine;
N*6*-tert-Butyl-N*2*-naphthalen-2-yl-9-(tetrahydro-pyran-2-yl)-9H-purine-2,6-diamine;
N*6*-tert-Butyl-N*2*-(2-methyl-quinolin-6-yl)-9-(tetrahydro-pyran-2-yl)-9H-purine-2,6-diamine;
N*6*-tert-Butyl-N*2*-(2-methyl-benzothiazol-5-yl)-9-(tetrahydro-pyran-2-yl)-9H-purine-2,6-diamine;
N*6*-tert-Butyl-N*2*-(2-tert-butyl-benzothiazol-6-yl)-9-(tetrahydro-pyran-2-yl)-9H-purine-2,6-diamine;
N*6*-Cycloheptyl-N*2*-quinolin-6-yl-9-(tetrahydro-pyran-2-yl)-9H-purine-2,6-diamine;
N*2*-(4-Benzothiazol-2-yl-phenyl)-N*6*-tert-butyl-9-(tetrahydro-pyran-2-yl)-9H-purine-2,6-diamine;
N*6*-tert-Butyl-N*2*-(6-methoxy-naphthalen-2-yl)-9-(tetrahydro-pyran-2-yl)-9H-purine-2,6-diamine;
N*6*-tert-Butyl-N*2*-[6-(2-morpholin-4-yl-ethoxy)-naphthalen-2-yl]-9-(tetrahydro-pyran-2-yl)-9H-purine-2,6-diamine;
5-{9-[Bis-(4-methoxy-phenyl)-methyl]-6-tert-butylamino-9H-purin-2-ylamino}-2-methyl-indole-1-carboxylic acid tert-butyl ester;
9-[Bis-(4-methoxy-phenyl)-methyl]-N*6*-tert-butyl-N*2*-(1H-indol-5-yl)-9H-purine-2,6-diamine;
9-[Bis-(4-methoxy-phenyl)-methyl]-N*6*-tert-butyl-8-ethyl-N*2*-[2-(2-morpholin-4-yl-ethoxy)-benzothiazol-6-yl]-9H-purine-2,6-diamine;

N*6*-tert-Butyl-8-ethyl-N*2*-[2-(2-morpholin-4-yl-ethoxy)-benzothiazol-6-yl]-9-(tetrahydro-pyran-2-yl)-9H-purine-2,6-diamine;
N*6*-tert-Butyl-8-isopropyl-N*2*-{1-methylene-3-[5-methyl-2-(2-morpholin-4-yl-ethoxy)-thiazol-4-yl]-allyl}-9-(tetrahydro-pyran-2-yl)-9H-purine-2,6-diamine;
N*6*-tert-Butyl-8-cyclopropyl-N*2*-{1-methylene-3-[5-methyl-2-(2-morpholin-4-yl-ethoxy)-thiazol-4-yl]-allyl}-9-(tetrahydro-pyran-2-yl)-9H-purine-2,6-diamine;
N*6*-tert-Butyl-8-cyclopentyl-N*2*-{1-methylene-3-[5-methyl-2-(2-morpholin-4-yl-ethoxy)-thiazol-4-yl]-allyl}-9-(tetrahydro-pyran-2-yl)-9H-purine-2,6-diamine;
N*2*-Benzothiazol-6-yl-N*6*-tert-butyl-8-cyclopropyl-9-(tetrahydro-pyran-2-yl)-9H-purine-2,6-diamine;
N*2*-Benzothiazol-6-yl-N*6*-tert-butyl-N*8*-(2,4-dimethoxy-benzyl)-9-(tetrahydro-pyran-2-yl)-9H-purine-2,6,8-triamine;
N*6*-tert-Butyl-N*8*-(2,4-dimethoxy-benzyl)-N*2*-naphthalen-2-yl-9-(tetrahydro-pyran-2-yl)-9H-purine-2,6,8-triamine;
N*6*-tert-Butyl-N*8*-(2,4-dimethoxy-benzyl)-N*8*-methyl-N*2*-naphthalen-2-yl-9-(tetrahydro-pyran-2-yl)-9H-purine-2,6,8-triamine;
N*2*-Benzothiazol-6-yl-N*6*-tert-butyl-8-(1-ethoxy-vinyl)-9-(tetrahydro-pyran-2-yl)-9H-purine-2,6-diamine;
tert-Butyl-(2-chloro-8-methyl-9H-purin-6-yl)-amine;
(2-Chloro-8-methyl-9H-purin-6-yl)-cycloheptyl-amine;
tert-Butyl-(2-chloro-8-ethyl-9H-purin-6-yl)-amine;
(2-Chloro-8-ethyl-9H-purin-6-yl)-(2,2,2-trifluoro-1-methyl-ethyl)-amine;
2-Chloro-8-ethyl-6-(2-methyl-pyrrolidin-1-yl)-9H-purine;
3-(2-Chloro-8-ethyl-9H-purin-6-ylamino)-butyramide;
3-(2-Chloro-8-ethyl-9H-purin-6-ylamino)-butyric acid ethyl ester;
tert-Butyl-(2-chloro-8-propyl-9H-purin-6-yl)-amine;
tert-Butyl-(2-chloro-8-isopropyl-9H-purin-6-yl)-amine;
tert-Butyl-(2-chloro-8-cyclopentyl-9H-purin-6-yl)-amine;
tert-Butyl-(2-chloro-8-cyclopropyl-9H-purin-6-yl)-amine;
Benzhydryl-[2-chloro-9-(tetrahydro-pyran-2-yl)-9H-purin-6-yl]-amine;
tert-Butyl-[2-chloro-9-(tetrahydro-pyran-2-yl)-9H-purin-6-yl]-amine;
[2-Chloro-9-(tetrahydro-pyran-2-yl)-9H-purin-6-yl]-cycloheptyl-amine;
{9-[Bis-(4-methoxy-phenyl)-methyl]-2-chloro-9H-purin-6-yl}-tert-butyl-amine;
{9-[Bis-(4-methoxy-phenyl)-methyl]-2-chloro-8-ethyl-9H-purin-6-yl}-tert-butyl-amine;
tert-Butyl-[2-chloro-8-ethyl-9-(tetrahydro-pyran-2-yl)-9H-purin-6-yl]-amine;
tert-Butyl-[2-chloro-8-isopropyl-9-(tetrahydro-pyran-2-yl)-9H-purin-6-yl]-amine;

tert-Butyl-[2-chloro-8-cyclopropyl-9-(tetrahydro-pyran-2-yl)-9H-purin-6-yl]-amine;
tert-Butyl-[2-chloro-8-cyclopentyl-9-(tetrahydro-pyran-2-yl)-9H-purin-6-yl]-amine;
tert-Butyl-[2-chloro-8-cyclopropyl-9-(tetrahydro-pyran-2-yl)-9H-purin-6-yl]-amine;
N*6*-tert-Butyl-2-chloro-N*8*-(2,4-dimethoxy-benzyl)-9-(tetrahydro-pyran-2-yl)-9H-purine-6,8-diamine;
N*6*-tert-Butyl-2-chloro-N*8*-(2,4-dimethoxy-benzyl)-N*8*-methyl-9-(tetrahydro-pyran-2-yl)-9H-purine-6,8-diamine;
tert-Butyl-[2-chloro-8-(1-ethoxy-vinyl)-9-(tetrahydro-pyran-2-yl)-9H-purin-6-yl]-amine;
9-[Bis-(4-methoxy-phenyl)-methyl]-2,6-dichloro-9H-purine;
N-(4-Amino-2,6-dichloro-pyrimidin-5-yl)-acetimidic acid ethyl ester;
N-(4-Amino-2,6-dichloro-pyrimidin-5-yl)-propionimidic acid ethyl ester;
N-(4-Amino-2,6-dichloro-pyrimidin-5-yl)-butyrimidic acid methyl ester;
N-(4-Amino-2,6-dichloro-pyrimidin-5-yl)-2-methyl-propionimidic acid ethyl ester;
N-(4-Amino-2,6-dichloro-pyrimidin-5-yl)-cyclopentanecarboximidic acid ethyl ester;
N-(4-Amino-2,6-dichloro-pyrimidin-5-yl)-cyclopropanecarboximidic acid ethyl ester;
6-(2-Morpholin-4-yl-ethoxy)-naphthalen-2-ylamine;
4-[2-(6-Bromo-naphthalen-2-yloxy)-ethyl]-morpholine;
5-Amino-2-methyl-indole-1-carboxylic acid tert-butyl ester;
2-Methyl-5-nitro-indole-1-carboxylic acid tert-butyl ester;
2-(2-Morpholin-4-yl-ethoxy)-benzothiazol-6-ylamine;
2-(2-Morpholin-4-yl-ethoxy)-6-nitro-benzothiazole;
[8-Bromo-2-chloro-9-(tetrahydro-pyran-2-yl)-9H-purin-6-yl]-tert-butyl-amine;
8-Bromo-2,6-dichloro-9-(tetrahydro-pyran-2-yl)-9H-purine; and
2,6-Dichloro-8-(1-ethoxy-vinyl)-9-(tetrahydro-pyran-2-yl)-9H-purine.

17. Use of a compound according to Claim 1 in the preparation of a pharmaceutical compositions for use in the treatment of a disease dependent on topoisomerase II.

18. A process to prepare a compound according to claim 4 comprising:

(A) reacting a substituted 9H-purin-6-ylamine of Formula (II) with an hereroaryl/aryl-amine to form a compound of Formula (I), or;



(II) (I)

Method A

(B) reacting a substituted 9H-purin-6-yl of Formula (IV), substituted with a protecting group, R_9, with an hereroaryl/aryl-amine using preferably a palladium catalysed S_NAr reaction and removing of the protecting group to form a compound of Formula (I); or



(IV) (III) (I)

Method B : R_9 protecting group with Pd caltalyzed amination

(C) reacting, in a solid phase, using a Rink acid resin, a substituted 9H-purin-6-yl, with an appropriate amine to afford substitution at the 6 position, followed by reaction with an hereroaryl/aryl-amine using preferably a palladium catalysed S_NAr reaction to afford substitution at the 2 position, cleavage from the resin and purification:



VI

(Ia)

(I)

Method C: solid phase synthesis

and, if desired, after reaction (A), (B) or (C), transforming an obtainable compound of Formula (I) into a different compound of Formula (I); transforming a salt of an obtainable compound of Formula (I) into the free compound or a different salt or an obtainable free compound of Formula (I) into a salt; and/or separating an obtainable mixture of isomers of compounds of Formula (I) into the individual isomers,

wherein R'_6, R_6, R_2, and R_8 are as defined in claim 4; and Y and R_9 are protecting groups.